Literature DB >> 28546072

Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.

Ingrid S Ganda1, Qian Zhong2, Mirabela Hali3, Ricardo L C Albuquerque4, Francine F Padilha5, Sandro R P da Rocha6, Judith A Whittum-Hudson7.   

Abstract

Peptide-based vaccines have emerged in recent years as promising candidates in the prevention of infectious diseases. However, there are many challenges to maintaining in vivo peptide stability and enhancement of peptide immunogenicity to generate protective immunity which enhances clearance of infections. Here, a dendrimer-based carrier system is proposed for peptide-based vaccine delivery, and shows its anti-microbial feasibility in a mouse model of Chlamydia trachomatis. Chlamydiae are the most prevalent sexually transmitted bacteria worldwide, and also the causal agent of trachoma, the leading cause of preventable infectious blindness. In spite of the prevalence of this infectious agent and the many previous vaccine-related studies, there is no vaccine commercially available. The carrier system proposed consists of generation 4, hydroxyl-terminated, polyamidoamine (PAMAM) dendrimers (G4OH), to which a peptide mimic of a chlamydial glycolipid antigen-Peptide 4 (Pep4, AFPQFRSATLLL) was conjugated through an ester bond. The ester bond between G4OH and Pep4 is expected to break down mainly in the intracellular environment for antigen presentation. Pep4 conjugated to dendrimer induced Chlamydia-specific serum antibodies after subcutaneous immunizations. Further, this new vaccine formulation significantly protected immunized animals from vaginal challenge with infectious Chlamydia trachomatis, and it reduced infectious loads and tissue (genital tract) damage. Pep4 conjugated to G4OH or only mixed with peptide provided enhanced protection compared to Pep4 and adjuvant (i.e. alum), suggesting a potential adjuvant effect of the PAMAM dendrimer. Combined, these results demonstrate that hydroxyl-terminated PAMAM dendrimer is a promising polymeric nanocarrier platform for the delivery of peptide vaccines and this approach has potential to be expanded to other infectious intracellular bacteria and viruses of public health significance.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chlamydia trachomatis; Infectious disease; Nanovaccine; PAMAM dendrimer; Subunit peptide vaccine

Mesh:

Substances:

Year:  2017        PMID: 28546072      PMCID: PMC5522616          DOI: 10.1016/j.ijpharm.2017.05.045

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  76 in total

Review 1.  Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery.

Authors:  S Sadekar; H Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2011-09-29       Impact factor: 15.470

2.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.

Authors:  R Esfand; D A. Tomalia
Journal:  Drug Discov Today       Date:  2001-04-01       Impact factor: 7.851

3.  Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.

Authors:  J D Carter; L R Espinoza; R D Inman; K B Sneed; L R Ricca; F B Vasey; J Valeriano; J A Stanich; C Oszust; H C Gerard; A P Hudson
Journal:  Arthritis Rheum       Date:  2010-05

Review 4.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

5.  Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers.

Authors:  J C Roberts; M K Bhalgat; R T Zera
Journal:  J Biomed Mater Res       Date:  1996-01

6.  Reactions of N-hydroxysulfosuccinimide active esters.

Authors:  P S Anjaneyulu; J V Staros
Journal:  Int J Pept Protein Res       Date:  1987-07

7.  Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers.

Authors:  Qian Zhong; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2016-02-10       Impact factor: 4.939

8.  PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections.

Authors:  Manoj K Mishra; Kishore Kotta; Mirabela Hali; Susan Wykes; Herve C Gerard; Alan P Hudson; Judith A Whittum-Hudson; Rangaramanujam M Kannan
Journal:  Nanomedicine       Date:  2011-05-19       Impact factor: 5.307

9.  Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.

Authors:  Saurabh Dixit; Shree R Singh; Abebayehu N Yilma; Ronald D Agee; Murtada Taha; Vida A Dennis
Journal:  Nanomedicine       Date:  2014-03-04       Impact factor: 5.307

Review 10.  Vaccine delivery using nanoparticles.

Authors:  Anthony E Gregory; Richard Titball; Diane Williamson
Journal:  Front Cell Infect Microbiol       Date:  2013-03-25       Impact factor: 5.293

View more
  7 in total

Review 1.  Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.

Authors:  Pavimol Angsantikul; Ronnie H Fang; Liangfang Zhang
Journal:  Bioconjug Chem       Date:  2017-12-27       Impact factor: 4.774

2.  The Immunogenicity of OMP31 Peptides and Its Protection Against Brucella melitensis Infection in Mice.

Authors:  Fengbo Zhang; Zhiwei Li; Bin Jia; Yuejie Zhu; Pan Pang; Chuntao Zhang; Jianbing Ding
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

Review 3.  Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections.

Authors:  Arturo Sánchez; Susana P Mejía; Jahir Orozco
Journal:  Molecules       Date:  2020-08-18       Impact factor: 4.411

Review 4.  Peptides and Dendrimers: How to Combat Viral and Bacterial Infections.

Authors:  Annarita Falanga; Valentina Del Genio; Stefania Galdiero
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

5.  In silico and in vivo studies of gp120-HIV-derived peptides in complex with G4-PAMAM dendrimers.

Authors:  Rodríguez-Fonseca Rolando Alberto; Bello Martiniano; Rojas-Hernández Saúl; García-Machorro Jazmín; Gutiérrez-Sánchez Mara; Estrada-Pérez Alan Rubén; Fragoso-Vázquez Manuel Jonathan; Méndez-Méndez Juan Vicente; Correa-Basurto José
Journal:  RSC Adv       Date:  2020-05-27       Impact factor: 4.036

Review 6.  Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies.

Authors:  Valentina Del Genio; Rosa Bellavita; Annarita Falanga; Katel Hervé-Aubert; Igor Chourpa; Stefania Galdiero
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

Review 7.  Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases.

Authors:  Miguel Ángel Ortega; Alberto Guzmán Merino; Oscar Fraile-Martínez; Judith Recio-Ruiz; Leonel Pekarek; Luis G Guijarro; Natalio García-Honduvilla; Melchor Álvarez-Mon; Julia Buján; Sandra García-Gallego
Journal:  Pharmaceutics       Date:  2020-09-14       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.